GlassScriptPhysician profile
Kristal Ledbetter
NPI 1467137018
$2,656.62
in general payments reported to CMS, 2019-2025
23 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $133 · 2024: $939 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $735.06 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Grifols USA, LLC | $559.01 | 2023-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $236.15 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $221.22 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novo Nordisk INC | $144.52 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $143.30 | 2023-2025 | Glassia, Vpriv |
| Mallinckrodt Hospital Products INC. | $95.76 | 2025 | Acthar |
| Insmed, INC. | $73.14 | 2024-2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $70.66 | 2025 | Zepbound, Mounjaro |
| Pulmonx Corporation | $52.35 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Viatris Specialty LLC | $46.47 | 2025 | Yupelri |
| Lundbeck LLC | $46.36 | 2024 | Vyepti |
| Axsome Therapeutics, INC. | $29.93 | 2024 | Sunosi |
| Verona Pharma, INC. | $28.25 | 2025 | Ohtuvayre |
| Medtronic, INC. | $26.63 | 2025 | Venaseal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $21.43 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $20.58 | 2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.53 | 2025 | |
| Abbvie INC. | $20.00 | 2024 | |
| Exact Sciences Corporation | $17.27 | 2025 | Cologuard Collection Kit |
| Baxter Healthcare | $17.10 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.00 | 2025 | Rexulti |
| Pfizer INC. | $14.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristal Ledbetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.